These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 6539100)

  • 1. [Introduction of new screening system in National Cancer Institute].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 1984 May; 11(5):1134-9. PubMed ID: 6539100
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical development of anticancer agents--a National Cancer Institute perspective.
    Marsoni S; Wittes R
    Cancer Treat Rep; 1984 Jan; 68(1):77-85. PubMed ID: 6362870
    [No Abstract]   [Full Text] [Related]  

  • 3. Screening at the National Cancer Institute.
    Goldin A; Venditti JM; Carter SK
    Natl Cancer Inst Monogr; 1977 Mar; (45):37-48. PubMed ID: 337155
    [No Abstract]   [Full Text] [Related]  

  • 4. The preclinical new drug research program of the National Cancer Institute.
    Driscoll JS
    Cancer Treat Rep; 1984 Jan; 68(1):63-76. PubMed ID: 6692438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The National Cancer Institute antitumor drug discovery program, current and future perspectives: a commentary.
    Venditti JM
    Cancer Treat Rep; 1983 Sep; 67(9):767-72. PubMed ID: 6883352
    [No Abstract]   [Full Text] [Related]  

  • 6. Preclinical toxicology protocols of the Laboratory of Toxicology.
    Prieur DJ; Young DM; Davis RD; Cooney DA; Guarino AM
    Natl Cancer Inst Monogr; 1977 Mar; (45):159-77. PubMed ID: 412104
    [No Abstract]   [Full Text] [Related]  

  • 7. Developing new agents for the treatment of childhood cancer.
    Kurmasheva R; Morton C; Houghton PJ
    Curr Opin Investig Drugs; 2005 Dec; 6(12):1215-27. PubMed ID: 16372407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical predictivity of transplantable tumor systems in the selection of new drugs for solid tumors: rationale for a three-stage strategy.
    Staquet MJ; Byar DP; Green SB; Rozencweig M
    Cancer Treat Rep; 1983 Sep; 67(9):753-65. PubMed ID: 6883351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New approaches in experimental cancerology: in search of therapeutic models].
    Guilbaud N; Kraus-Berthier L; Meyer-Losic F; Pierré A; Hickman J
    Bull Cancer; 2001 Jan; 88(1):75-84. PubMed ID: 11182656
    [No Abstract]   [Full Text] [Related]  

  • 10. Current investigational drugs of interest in the Chemotherapy Program of the National Cancer Institute.
    Carter SK; Slavik M
    Natl Cancer Inst Monogr; 1977 Mar; (45):101-21. PubMed ID: 73134
    [No Abstract]   [Full Text] [Related]  

  • 11. Liposomes as drug carriers in cancer therapy: hyperthermia and pH sensitivity as modalities for targeting.
    Yatvin MB; Cree TC; Tegmo-Larsson IM; Gipp JJ
    Strahlentherapie; 1984 Dec; 160(12):732-40. PubMed ID: 6393456
    [No Abstract]   [Full Text] [Related]  

  • 12. [Antitumor drug screening at the National Cancer Institute, U.S.A].
    Tsuruo T
    Gan To Kagaku Ryoho; 1987 Oct; 14(10):2809-15. PubMed ID: 3310904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modified protocol for the testing of new synthetics in the L1210 lymphoid leukemia murine model in the DR&D program, DCT, NCI.
    Geran RI; Greenberg NH; Macdonald MM; Abbott BJ
    Natl Cancer Inst Monogr; 1977 Mar; (45):151-3. PubMed ID: 927490
    [No Abstract]   [Full Text] [Related]  

  • 14. [Models and methods used for the selection of antitumor preparations in the USSR and abroad].
    Sof'ina ZP
    Vopr Onkol; 1976; 22(4):82-96. PubMed ID: 1274284
    [No Abstract]   [Full Text] [Related]  

  • 15. Interest of the National Cancer Institute in comparative pharmacology.
    Saunders JP
    Fed Proc; 1967; 26(4):1071-3. PubMed ID: 4961512
    [No Abstract]   [Full Text] [Related]  

  • 16. Criteria associated with destruction of leukemia and solid tumor cells in animals.
    Skipper HE
    Cancer Res; 1967 Dec; 27(12):2636-45. PubMed ID: 6082300
    [No Abstract]   [Full Text] [Related]  

  • 17. [Experimental methodology for the selection of potential anticancer agents].
    Pérez Mínguez F; Llombart Bosch A
    Rev Esp Oncol; 1982; 29(4):593-602. PubMed ID: 6927364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening of Philippine medicinal plants for anticancer agents using CCNSC Protocols.
    Masilungan VA; Vadlamudi S; Goldin A
    Cancer Chemother Rep 2; 1971 Apr; 2(1):135-40. PubMed ID: 5109412
    [No Abstract]   [Full Text] [Related]  

  • 19. Antitumor screening procedures of the National Cancer Institute.
    Schepartz SA
    Jpn J Antibiot; 1977 Dec; 30 Suppl():35-40. PubMed ID: 612710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976-1982, and future directions.
    Venditti JM; Wesley RA; Plowman J
    Adv Pharmacol Chemother; 1984; 20():1-20. PubMed ID: 6398966
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.